IDEAYA Biosciences Inc
NASDAQ:IDYA
IDEAYA Biosciences Inc
Cash from Operating Activities
IDEAYA Biosciences Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
IDEAYA Biosciences Inc
NASDAQ:IDYA
|
Cash from Operating Activities
-$149.7m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$16.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
12%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
||
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$7.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
-$842.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
18%
|
IDEAYA Biosciences Inc
Glance View
IDEAYA Biosciences Inc. is a beacon of innovation in the burgeoning field of precision oncology, focused primarily on advancing synthetic lethality - a cutting-edge approach to cancer therapy. Founded in 2015 and headquartered in South San Francisco, California, the company is deeply entrenched in the research and development of targeted therapies to combat genetically defined cancers. The core strategy revolves around discovering and developing small molecule inhibitors that precisely align with defined genetic alterations in cancer patients. By doing so, IDEAYA aims to exploit the weaknesses in specific cancer cells while sparing normal, healthy cells, thereby enhancing treatment efficacy and minimizing adverse effects. This targeted approach represents a significant shift from traditional broad-spectrum chemotherapy, offering a more personalized and efficient treatment pathway. In terms of revenue generation, IDEAYA operates primarily through collaborations and partnerships with larger pharmaceutical companies, which are attracted by its robust pipeline and innovative approach. These strategic alliances often involve milestone payments, research funding, and potential royalties on future sales. Furthermore, IDEAYA occasionally benefits from upfront payments when entering these collaborations, adding to its revenue stream. The company's business model is not solely reliant on direct sales of developed therapies but on leveraging its scientific prowess to create valuable partnership opportunities. By effectively bridging the gap between research and clinical application, IDEAYA captivates not only the interest of the pharmaceutical giants but also the investment community, eager to back a venture at the frontier of precision cancer treatment.
See Also
What is IDEAYA Biosciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-149.7m
USD
Based on the financial report for Sep 30, 2024, IDEAYA Biosciences Inc's Cash from Operating Activities amounts to -149.7m USD.
What is IDEAYA Biosciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-31%
Over the last year, the Cash from Operating Activities growth was -30%. The average annual Cash from Operating Activities growth rates for IDEAYA Biosciences Inc have been -43% over the past three years , -31% over the past five years .